After years of academic and early-stage biotech development, exosomes finally entered the clinic last year, when Codiak launched their Phase I/II trial in advanced solid tumors. Now Evox, their chief rival in the space, is plotting their own path to humans, even if they still have a ways to go.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,